Comparison of Two Different Surgical Approaches To Increase Peri-Implant Mucosa Thickness
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02450383 |
|
Recruitment Status :
Completed
First Posted : May 21, 2015
Results First Posted : September 18, 2017
Last Update Posted : October 18, 2017
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
The purpose of this non-inferiority trial is to determine the clinical efficacy of acellular dermal matrix (ADM) in the augmentation of the gum around dental implants as compared to an autologous gum graft (sCTG) obtained from the palate (roof of the mouth) in human adults.
AlloDerm is regulated by the US Food and Drug Administration (FDA) as human tissue for transplantation. AlloDerm is processed and marketed in accordance with the FDA's requirements for banked human tissue (21 CFR, Part 1270 and Part 1271) and Standards for Tissue Banking of the American Association of Tissue Banks (AATB).
Twenty adult subjects will be recruited who are in need of dental implant placement with simultaneous gum grafting to increase the thickness of the facial mucosa. Half of the subjects will be randomized to the ADM group and half will be randomized to the sCTG group. The surgical intervention will be performed according to the protocol and subjects will return for follow-up 2, 4, 8, and 16 weeks post-surgery for follow-up measurements of healing, gum thickness, subject perception of pain, and esthetic photographs.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Tooth Loss Peri-implant Mucosa Defect | Drug: Acellular Dermal Matrix Procedure: Autologous subepithelial connective tissue graft | Phase 4 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 20 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Single (Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | Comparison of Two Different Surgical Approaches to Increase Peri-Implant Mucosa Thickness: A Randomized Controlled Clinical Trial |
| Actual Study Start Date : | January 2015 |
| Actual Primary Completion Date : | September 2016 |
| Actual Study Completion Date : | September 2016 |
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: Control
Autologous subepithelial connective tissue graft
|
Procedure: Autologous subepithelial connective tissue graft
Placement of autologous subepithelial connective tissue graft on the buccal/coronal aspect of the alveolar ridge at the time of implant placement, following a two-stage approach
Other Name: sCTG |
|
Experimental: Experimental
Acellular Dermal Matrix
|
Drug: Acellular Dermal Matrix
Placement of acellular dermal matrix (Alloderm®) on the buccal/coronal aspect of the alveolar ridge at the time of implant placement, following a two-stage approach
Other Name: Alloderm® |
- Change in Buccal Peri-implant Mucosa Thickness Between Baseline and 16 Weeks After Surgery [ Time Frame: Baseline and 16 weeks after baseline ]Buccal mucosa thickness measurements were obtained by a calibrated, masked examiner using a custom-made stent and an endo file for precision and reproducibility between different time points
- Changes in Peri-implant Keratinized Mucosa Width (Apico-coronal) at 16 Weeks After Surgery [ Time Frame: Baseline to 16 weeks after baseline ]
- Patient-perceived Discomfort, Measured by VAS [ Time Frame: 2 weeks ]Patient-reported outcome measures of perceived discomfort using a visual analog scale (VAS) from 0 (no pain) to 100 (maximum pain) were recorded
- Wound Healing, Measured Using a Standardized Visual Wound Healing Index [ Time Frame: 2 weeks ]Wound healing status was evaluated by the same calibrated clinician using a standardized visual wound healing index at different time points A simple wound healing scoring system including 3 categories was used: 1- uneventful wound healing, 2- slight gingival edema, erythema or discomfort, 3- poor wound healing
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 80 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Inclusion criteria:
- Age: 18 to 80 years.
- Subjects must be able and willing to follow instructions related to the study procedures.
- Subjects must have read, understood and signed an informed consent form.
- At least one single-tooth edentulous site, with adjacent natural teeth, planned for tooth replacement therapy with an implant-supported restoration.
Exclusion criteria:
- Reported allergy or hypersensitivity to any of the products to be used in the study.
- Severe hematologic disorders, such as hemophilia or leukemia.
- Active severe infectious diseases that may compromise normal healing.
- Liver or kidney dysfunction/failure.
- Currently under cancer treatment or within 18 months from completion of radio- or chemotherapy.
- Subjects with uncontrolled diabetes, defined as Hba1c > 6.5% (According to the American Diabetes Association 2014 Guidelines)
- Pregnant women or nursing mothers.
- Smokers: Subjects who have smoked within 6 months of study onset.
- Concomitant medications for systemic conditions that may affect the outcomes of the study.
- Any other non-specified reason that from the point of view of the investigators will make a candidate not a suitable subject for the study (e.g. limited mouth opening).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02450383
| United States, Iowa | |
| University of Iowa College of Dentistry - Craniofacial Clinical Research Center and Department of Periodontics | |
| Iowa City, Iowa, United States, 52242 | |
| Principal Investigator: | Gustavo Avila-Ortiz, DDS, MS, PhD | University of Iowa College of Dentistry |
| Responsible Party: | Gustavo Avila-Ortiz, Associate Professor, University of Iowa |
| ClinicalTrials.gov Identifier: | NCT02450383 |
| Other Study ID Numbers: |
201407810 |
| First Posted: | May 21, 2015 Key Record Dates |
| Results First Posted: | September 18, 2017 |
| Last Update Posted: | October 18, 2017 |
| Last Verified: | September 2017 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Plan Description: | We are not planning on sharing IPD |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
| Product Manufactured in and Exported from the U.S.: | Yes |
|
Tooth Loss Periodontal Diseases Mouth Diseases Stomatognathic Diseases Tooth Diseases |

